1. Home
  2. ATYR vs RMR Comparison

ATYR vs RMR Comparison

Compare ATYR & RMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • RMR
  • Stock Information
  • Founded
  • ATYR 2005
  • RMR 1986
  • Country
  • ATYR United States
  • RMR United States
  • Employees
  • ATYR N/A
  • RMR N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • RMR Professional Services
  • Sector
  • ATYR Health Care
  • RMR Consumer Discretionary
  • Exchange
  • ATYR Nasdaq
  • RMR Nasdaq
  • Market Cap
  • ATYR 330.7M
  • RMR 306.9M
  • IPO Year
  • ATYR 2015
  • RMR N/A
  • Fundamental
  • Price
  • ATYR $3.87
  • RMR $17.09
  • Analyst Decision
  • ATYR Strong Buy
  • RMR Buy
  • Analyst Count
  • ATYR 6
  • RMR 2
  • Target Price
  • ATYR $18.60
  • RMR $32.00
  • AVG Volume (30 Days)
  • ATYR 2.1M
  • RMR 173.0K
  • Earning Date
  • ATYR 03-13-2025
  • RMR 05-06-2025
  • Dividend Yield
  • ATYR N/A
  • RMR 10.56%
  • EPS Growth
  • ATYR N/A
  • RMR N/A
  • EPS
  • ATYR N/A
  • RMR 0.97
  • Revenue
  • ATYR $235,000.00
  • RMR $199,940,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • RMR $371.91
  • Revenue Next Year
  • ATYR $873.22
  • RMR $1.02
  • P/E Ratio
  • ATYR N/A
  • RMR $17.60
  • Revenue Growth
  • ATYR N/A
  • RMR N/A
  • 52 Week Low
  • ATYR $1.42
  • RMR $16.89
  • 52 Week High
  • ATYR $4.66
  • RMR $26.43
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 54.43
  • RMR 32.42
  • Support Level
  • ATYR $2.98
  • RMR $17.97
  • Resistance Level
  • ATYR $4.32
  • RMR $17.36
  • Average True Range (ATR)
  • ATYR 0.41
  • RMR 0.42
  • MACD
  • ATYR 0.06
  • RMR -0.09
  • Stochastic Oscillator
  • ATYR 72.14
  • RMR 9.24

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About RMR The RMR Group Inc.

The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.

Share on Social Networks: